NEW YORK – In a new study published in JAMA Network Open, researchers have analyzed genomic, transcriptomic, and immune profiles of patients who participated in a Phase II clinical trial and associated their immune functional states with distinct classes of long noncoding RNA (lncRNA). They found that these classes appeared to be predictive of the patients' immunotherapy outcomes.